Table I.
Comparison of demographic and immune parameters between rheumatoid arthritis patients classified on the basis of DAS28-CRP(3) into remission and active disease
| Demographic and immune variables# | Remission-treated patients (n=52) | DMARD-naÏve patients (n=20) |
|---|---|---|
| DAS28-CRP(3) groups | ≤2.6 | >2.6 |
| Age (yr) | 47.31±10.05 | 44.55±11.96 |
| Gender (male/female) | 10/42 | 1/19 |
| Duration of illness (months) | 60 (7-240) | 15 (3-120)*** |
| Neutrophil to lymphocyte ratio | 2.33 (1.09-6.65) | 2.44 (1.44-5.82) |
| CD3 (cells/μl) | 701.5 (176-2130) | 804.5 (374-1485) |
| CD4 (cells/μl) | 434.72 (142.65-1420.98) | 508.40 (198.99-850.88) |
| FOXP3 (cells/μl) | 0.209 (0-9.26) | 0.32 (0-3.41) |
| CD19 (cells/μl) | 137 (10-321) | 151 (27-481) |
| CD3:CD19 ratio | 4.74 (1.61-54.4) | 5.1 (0.89-18.22) |
| FOXP3:CD4 ratio | 0 (0-0.05) | 0.001 (0-0.012) |
#Continuous variables represented as mean±SD for normal data and median (range) for data without normal distribution. Counts are given for categorical variables. ***P<0.001 compared to treated patients. DMARD, disease-modifying anti-rheumatic drug; CRP, C-reactive protein; DAS, disease activity score